{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in other situations. Adverse events were graded for severity according to the NCI CTCAE, version 3.0: Grade 1, mild; Grade 2, moderate; Grade 3 (G3), severe; Grade 4 (G4), life-threatening or disabling; Grade 5, death.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATP Population","reportingStatus":"POSTED","timeFrame":"From Baseline to Follow-up (up to 6.230 years)","title":"Number of Participants With Any Adverse Event (Serious and Non-serious) of the Indicated Severity, Per National Cancer Institute (NCI) Common Terminology Criteria in Adverse Events (CTCAE)","type":"PRIMARY","unitOfMeasure":"participants"}